Department of Clinical Pathology, Sunnybrook Health Sciences Centre, Toronto, Canada.
Crit Rev Clin Lab Sci. 2011 Jul-Aug;48(4):171-95. doi: 10.3109/10408363.2011.620601.
Numerous established and potential drug interactions with methadone are clinically important in people treated with methadone either for addiction or for chronic pain. Methadone users often have comorbidities and are prescribed drugs that may interact with methadone. Methadone is extensively metabolized by cytochrome P450 (CYP) 3A4 and to a lesser extent by CYP 1A2, 2D6, 2D8, 2C9/2C8, 2C19, and 2B6. Eighty-six percent of methadone is protein bound, predominately to α1-acid glycoprotein (AGP). Polymorphisms in or interactions with CYPs that metabolize methadone, changes in protein binding, and other pathophysiological conditions affect the pharmacokinetic properties of methadone. It is critical for health care providers who treat patients on methadone to have adequate information on the interactions of methadone with other drugs of abuse and other medications. We set out to describe drug-drug interactions as well as physiological and pathophysiological factors that may impact the pharmacokinetics of methadone. Using MEDLINE, we conducted a systematic search for papers and related abstracts published between 1966 and June 2010. Keywords that included methadone, drug-drug interactions, CYP P450 and AGP identified a total of 7709 papers. Other databases, including the Cochrane Database of Systematic Reviews and Scopus, were also searched; an additional 929 papers were found. Final selection of 286 publications was based on the relevance of each paper to the topic. Over 50 such interactions were found. Interactions of methadone with other drugs can lead to increased or decreased methadone drug levels in patients and result in potential overdose or withdrawal, respectively. The former can contribute to methadone's fatality. Prescribers of methadone and pharmacists should enquire about any new medications (including natural products and over-the-counter medications) periodically, and especially when an otherwise stable patient suddenly experiences drug craving, withdrawal or intoxication.
美沙酮与许多已确定和潜在的药物相互作用,对于接受美沙酮治疗成瘾或慢性疼痛的患者具有重要的临床意义。美沙酮使用者常合并多种疾病,并同时服用可能与美沙酮相互作用的药物。美沙酮主要通过细胞色素 P450(CYP)3A4 代谢,其次为 CYP1A2、2D6、2D8、2C9/2C8、2C19 和 2B6。86%的美沙酮与蛋白结合,主要与α1-酸性糖蛋白(AGP)结合。美沙酮代谢的 CYP 基因多态性或相互作用、蛋白结合变化以及其他病理生理状况,都会影响美沙酮的药代动力学特性。因此,治疗美沙酮患者的医护人员需要充分了解美沙酮与其他滥用药物和其他药物的相互作用。我们旨在描述可能影响美沙酮药代动力学的药物-药物相互作用以及生理和病理生理因素。我们使用 MEDLINE 对 1966 年至 2010 年 6 月期间发表的论文和相关摘要进行了系统搜索。包括美沙酮、药物-药物相互作用、CYP P450 和 AGP 等关键词共检索到 7709 篇论文。还检索了其他数据库,包括 Cochrane 系统评价数据库和 Scopus,又发现了 929 篇论文。最终选择了 286 篇与主题相关的出版物。发现了 50 多种相互作用。美沙酮与其他药物的相互作用可导致患者体内美沙酮药物水平升高或降低,从而分别导致潜在的药物过量或戒断。前者可能导致美沙酮死亡。开美沙酮处方的医生和药剂师应定期询问患者是否使用新的药物(包括天然产品和非处方药),尤其是当病情稳定的患者突然出现药物渴求、戒断或中毒时。